Genomic analysis revealed an amplification of PIK3CA in 3.5% of CLL patients, which is perhaps surprising when all the significant pharmaceutical effort to inhibit the PI3K pathway in this malignancy is considered (37). The gene discussed is PIK3CA; the disease is B-cell chronic lymphocytic leukemia.